Solid cancer: Evaluating potential efficacy of epigenetic drugs

Abstract

Current generation of targeted cancer drugs in the treatment of solid cancers, with the exceptions of trastuzumab and vemurafenib, resistance and disease progression limit the effectiveness of most signal transduction inhibitors available. Epigenomic drugs and microRNAs-based agents represent one of promising categories in clinical development to increase tumor cells sensitivity to combined therapeutics. Here, I discuss latest data and perspectives in overcoming current therapy resistance by treating solid tumors.